Important Information for Neumora Therapeutics, Inc. (NMRA) Investors: Rosen Law Firm Reminds Investors of the Lead Plaintiff Deadline in Securities Class Action
New York, NY – March 2, 2025
Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) of the important April 7, 2025 lead plaintiff deadline in the securities class action first filed by the firm. The lawsuit was filed against Neumora and certain of its top executives in the United States District Court for the Southern District of New York.
What is the Securities Class Action About?
The complaint alleges that Neumora and its executives violated the Securities Act of 1933 by making false and/or misleading statements and/or failing to disclose material information in the Offering Documents related to Neumora’s business, financial condition, and prospects.
Who is Affected?
If you purchased Neumora common stock during the class period, which began on September 15, 2023, the date of the IPO, and ended on September 29, 2023, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
What Should Investors Do?
To join the Neumora class action, investors should contact the Rosen Law Firm by calling Phillip Kim, Esq. or Daniel Sadeh at 212-686-1060 or via email at [email protected] or [email protected] or via the firm’s website, rosenlegal.com for information on the class action.
What Does This Mean for Me?
If you purchased Neumora common stock during the class period, this means that you may be able to recover your losses through the securities class action. The lead plaintiff deadline is an important date in the litigation process, and investors who wish to participate must act before this date to be eligible to share in any potential recovery.
What Does This Mean for the World?
The Neumora securities class action is an example of how the legal system holds companies and their executives accountable for making false or misleading statements in connection with their initial public offerings. The lawsuit seeks to recover damages for investors who suffered losses as a result of these alleged misrepresentations.
Conclusion
If you purchased Neumora common stock during the class period and believe that you may be entitled to compensation, it is important to act before the lead plaintiff deadline on April 7, 2025. Contact the Rosen Law Firm at 212-686-1060 or via email at [email protected] or [email protected] or through the firm’s website, rosenlegal.com, to learn more about the class action and your potential eligibility to recover your losses.
- Rosen Law Firm reminds Neumora Therapeutics, Inc. (NMRA) investors of the April 7, 2025 lead plaintiff deadline in the securities class action.
- Investors who purchased Neumora common stock during the class period may be entitled to compensation.
- To join the class action, investors should contact the Rosen Law Firm before the lead plaintiff deadline.
- The Neumora securities class action seeks to recover damages for investors who suffered losses due to alleged misrepresentations.
